Age Related Macular Degeneration, Epiretinal Membrane
Conditions
Keywords
choroidal neovascularization, epiretinal membrane, anti-VEGF
Brief summary
Study designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
Detailed description
Gass in 1987 described three cases of epiretinal membrane (ERM) associated with wet macular degeneration. Since then we have seen that is not rare to find the coexistence of these entities. An ERM may produce intrinsic disorganization of the outer retina leading to persistent increased macular thickness and/or edema. This persistent edema may affect the effectiveness in the treatment of exudative age-related macular degeneration (eAMD). Therefore, this study was designed to evaluate the effect of significant ERM on the visual and anatomic outcomes of intravitreal anti-VEGF therapy for eAMD.
Interventions
None listed
Sponsors
New England Retina Associates
Study design
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
58 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Significant epiretinal membrane * Anti-VEGF treatment for age-related macular degeneration
Exclusion criteria
* Uveitis * Macular disorders * Diabetic retinopathy * Vascular occlusions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Best corrected visual acuity | 12 months | Evaluate the best visual acuity during the follow up. |
| Central macular thickness | 12 months | Evaluation of the retinal thickness changes with anti-VEGF treatment |
| Fluorescein angiogram | 12 months | Evaluation of changes in lesion size during follow-up. |
Outcome results
None listed